Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate

Jake G. Besch-Stokes; Meera H. Patel; Caitlin M. Brumfiel; Collin M. Costello; William Rule; Allison Rosenthal; Mark R. Pittelkow; David J. Dicaudo; Aaron R. Mangold

doi:10.5070/D327955138

Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate

Jake G. Besch-Stokes, Meera H. Patel, Caitlin M. Brumfiel, Collin M. Costello, William Rule, Allison Rosenthal, Mark R. Pittelkow, David J. Dicaudo, Aaron R. Mangold

Research output: Contribution to journal › Article › peer-review

Abstract

Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.

Original language	English (US)
Article number	8
Journal	Dermatology Online Journal
Volume	27
Issue number	9
DOIs	https://doi.org/10.5070/D327955138
State	Published - 2021

Keywords

B-cell disorders
Methotrexate
Pseudolymphoma
Rituximab

ASJC Scopus subject areas

Dermatology

Access to Document

10.5070/D327955138

Cite this

@article{27ecc19a22f74c508f5cf03729158622,

title = "Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate",

abstract = "Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.",

keywords = "B-cell disorders, Methotrexate, Pseudolymphoma, Rituximab",

author = "Besch-Stokes, {Jake G.} and Patel, {Meera H.} and Brumfiel, {Caitlin M.} and Costello, {Collin M.} and William Rule and Allison Rosenthal and Pittelkow, {Mark R.} and Dicaudo, {David J.} and Mangold, {Aaron R.}",

year = "2021",

doi = "10.5070/D327955138",

language = "English (US)",

volume = "27",

journal = "Dermatology Online Journal",

issn = "1087-2108",

publisher = "Department of Dermatology UC Davis",

number = "9",

}

TY - JOUR

T1 - Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate

AU - Besch-Stokes, Jake G.

AU - Patel, Meera H.

AU - Brumfiel, Caitlin M.

AU - Costello, Collin M.

AU - Rule, William

AU - Rosenthal, Allison

AU - Pittelkow, Mark R.

AU - Dicaudo, David J.

AU - Mangold, Aaron R.

PY - 2021

Y1 - 2021

N2 - Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.

AB - Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.

KW - B-cell disorders

KW - Methotrexate

KW - Pseudolymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85120493307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120493307&partnerID=8YFLogxK

U2 - 10.5070/D327955138

DO - 10.5070/D327955138

M3 - Article

C2 - 34755980

AN - SCOPUS:85120493307

SN - 1087-2108

VL - 27

JO - Dermatology Online Journal

JF - Dermatology Online Journal

IS - 9

M1 - 8

ER -

Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this